Early minimal residual disease assessment after AML induction with fludarabine, cytarabine and idarubicin (FLAI) provides the most useful prognostic information.
Paola MinettoFabio GuoloMarino ClavioAnnalisa KunklNicoletta ColomboEnrico CarminatiGiuseppina FugazzaSimona MatareseDaniela GuardoFilippo BalleriniCarmen Di GraziaAnna M RaiolaAntonia CagnettaMichele CeaMaurizio MiglinoRoberto M LemoliMarco GobbiPublished in: British journal of haematology (2018)